Supplementary File

Additional Supporting Information may be found in the online version of this article at the publisher’s website.

SUPPLEMENTARY APPENDIX

Appendix S1. Search strategy.

Table S1. Characteristics of the studies included in the meta-analysis.

Table S2 Summary of Odds ratio of psychiatric disorders and mortality in SLE patients receiving belimumab 10mg/kg compared with placebo.

Figure S1. Odds ratio of all-cause mortality in SLE patients receiving belimumab compared with placebo using peto method.

Figure S2. Odds ratio of all psychiatric disorders in SLE patients receiving belimumab compared with placebo after exclusion of conference abstracts.

Figure S3. Odds ratio of all-cause mortality in patients with immune-mediated diseases receiving belimumab compared with placebo after exclusion of conference abstracts.

Figure S4. Odds ratio of serious psychiatric disorders in SLE patients receiving belimumab group compared with placebo using peto method.

Figure S5. Odds ratio of suicidal ideation or behavior in SLE patients receiving belimumab group compared with placebo using peto method.

Figure S6. Odds ratio of depression in SLE patients receiving belimumab group compared with placebo using peto method.

Figure S7. Funnel plots for the meta-analysis of belimumab versus placebo, regarding (A) all psychiatric disorders, (B) all-cause mortality, (C) serious psychiatric disorders, (D) nonserious psychiatric disorders, (E) suicidal ideation or behavior, and (F) depression. SE: standard error; OR: odds ratio.